# Global Burden of Deep Neck Space Abscesses: Epidemiology, Challenges, and Outcomes

**Authors:** Antonino Maniaci, Francesco Chiari, Pierre Guarino, Luigi La Via, Mario Lentini, Salvatore Lavalle, Paolo Boscolo-Rizzo, Luigi Angelo Vaira, Jerome Rene Lechien

PMC · DOI: 10.3390/jpm16030146 · 2026-03-03

## TL;DR

Deep neck space abscesses are increasing globally, with higher risks for people with diabetes and other conditions, and require prompt treatment to avoid severe complications.

## Contribution

This review provides a comprehensive synthesis of DNSA epidemiology, challenges, and outcomes to guide global prevention and management strategies.

## Key findings

- DNSA incidence is rising in both high-income and resource-limited settings.
- Diabetes and immunosuppression are strongly linked to poor DNSA outcomes.
- Mortality ranges from 1.6% to 7.6%, with higher rates in cases involving mediastinitis.

## Abstract

Background/Objectives: Deep neck space abscesses (DNSAs), representing severe suppurative infections, continue to pose a significant global health challenge due to their morbidity, mortality, and evolving epidemiology. This review synthesizes existing knowledge regarding DNSA definitions, anatomic basis, epidemiological trends, microbiology, clinical presentation, diagnostic strategies, treatment paradigms, outcomes, health system challenges, and disparities to guide global efforts in DNSA prevention, management, and research. Methods: A structured narrative review was performed following SANRA guidelines. PubMed/MEDLINE and the Cochrane Library were searched from January 2000 to May 2025, retrieving 1102 records. After screening, 49 studies met the inclusion criteria. Data were extracted using standardized templates and synthesized thematically. Results: During the period 2004–2015, annual case increases were reported in a Finnish population-based retrospective cohort (n = 277), going from 14 to 24 subjects, and for a UK tertiary center retrospective series, going from 1 to 15 cases annually (2006–2015) (Pearson’s correlation, r = 0.9; p = 0.00019). The microbiological environment is mostly polymicrobial, composed of group streptococci and staphylococcus strains and anaerobes. Factors associated with poor outcomes include diabetes mellitus (adjusted hazard ratio of 10.7 [95% CI 6.0–19.1] in a retrospective, population-based cohort of 12,738 diabetic patients compared to 50,952 individuals without diabetes), immunosuppressed state, elderly age, and multispace involvement. Diagnosis relies on contrast-enhanced CT imaging (sensitivity > 90%), and treatment consists of early multidisciplinary intervention combining empiric broad-spectrum antibiotics with surgical drainage in 60–97% of cases. Mortality ranges from 1.6% to 7.6%, with higher rates in cases complicated by mediastinitis (up to 40%). Conclusions: DNSAs demonstrate a clear upward incidence trend across high-income and resource-limited settings. Establishing standardized DNSA registries, validating risk-stratification tools, reinforcing antimicrobial stewardship to address rising resistance, and implementing early detection protocols in primary care remain critical priorities. While emerging technologies, including rapid molecular diagnostics and AI-based decision support, represent promising research directions, current DNSA management relies fundamentally on conventional clinical assessment, prompt imaging, and coordinated multidisciplinary care.

## Linked entities

- **Diseases:** diabetes mellitus (MONDO:0005015)

## Full-text entities

- **Genes:** CYP3A4 (cytochrome P450 family 3 subfamily A member 4) [NCBI Gene 1576] {aka CP33, CP34, CYP3A, CYP3A3, CYPIIIA3, CYPIIIA4}, CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}, CYP4F3 (cytochrome P450 family 4 subfamily F member 3) [NCBI Gene 4051] {aka CPF3, CYP4F, CYPIVF3, LTB4H}, CSF2 (colony stimulating factor 2) [NCBI Gene 1437] {aka CSF, GMCSF}, CYP2C19 (cytochrome P450 family 2 subfamily C member 19) [NCBI Gene 1557] {aka CPCJ, CYP2C, CYPIIC17, CYPIIC19, P450C2C, P450IIC19}, NAT2 (N-acetyltransferase 2) [NCBI Gene 10] {aka AAC2, NAT-2, PNAT}
- **Diseases:** dyspnea (MESH:D004417), Klebsiella pneumoniae (MESH:D007710), chronic renal or liver disease (MESH:D051436), Morbidity (OMIM:614963), neurologic sequelae (MESH:D009422), COVID (MESH:D000086382), edema (MESH:D004487), tachycardia (MESH:D013610), immunodeficiency (MESH:D007153), lymphadenitis (MESH:D008199), deep neck infection (MESH:D006258), jugular venous thrombosis (MESH:D020246), diabetes (MESH:D003920), Febrile (MESH:D000071072), thrombosis (MESH:D013927), inflammation (MESH:D007249), dysphagia (MESH:D003680), Ludwig's angina (MESH:D008158), oral and oropharyngeal infections (MESH:D009959), renal failure (MESH:D051437), acute or chronic sinusitis (MESH:D000208), Type 1 diabetes (MESH:D003922), infectious disease (MESH:D003141), septic (MESH:D001170), complications (MESH:D008107), mucosal damage (MESH:D052016), pain (MESH:D010146), fever (MESH:D005334), ESBL (MESH:C579922), toxicity (MESH:D064420), sore throat (MESH:D010612), Cardiovascular disease (MESH:D002318), airway compromise (MESH:D000402), DNM (MESH:D008480), postoperative pain (MESH:D010149), adenoid infections (MESH:D003528), staphylococcal (MESH:D011023), lymphadenopathy (MESH:D008206), parotitis (MESH:D010309), necrosis (MESH:D009336), scars (MESH:D002921), submandibular sialadenitis (MESH:D012793), odontogenic infections (MESH:D018126), influenza (MESH:D007251), sepsis (MESH:D018805), stridor (MESH:D012135), facial necrotizing fasciitis (MESH:D019115), cardiac or pulmonary disease (MESH:D006331), Neurovascular impairment (MESH:D013901), cysts (MESH:D003560), drooling (MESH:D012798), Gram (MESH:D016908), parapharyngeal disease (MESH:D004194), suppurative infections (MESH:D013492), tenderness (MESH:D063806), confusion (MESH:D003221), nerve injury (MESH:D000080902), agitation (MESH:D011595), acute tonsillitis (MESH:D014069), cancer (MESH:D009369)
- **Chemicals:** carbapenems (MESH:D015780), linezolid (MESH:D000069349), alcohol (MESH:D000438), fluoride (MESH:D005459), ceftriaxone (MESH:D002443), steroids (MESH:D013256), vancomycin (MESH:D014640), penicillin (MESH:D010406), clindamycin (MESH:D002981), macrolides (MESH:D018942), azoles (MESH:D001393), sulfonamide (MESH:D013449), DNSA (-), methicillin (MESH:D008712), ampicillin-sulbactam (MESH:C035444)
- **Species:** Prevotella (genus) [taxon 838], Bacteroides (genus) [taxon 816], Streptococcus pneumoniae (species) [taxon 1313], Respiratory syncytial virus (no rank) [taxon 12814], Streptococcus sp. 'group A' (species) [taxon 36470], Streptococcus anginosus (species) [taxon 1328], Homo sapiens (human, species) [taxon 9606], Streptococcus viridans (species) [taxon 78535], Streptococcus pyogenes (species) [taxon 1314], Klebsiella pneumoniae (species) [taxon 573], Streptococcus milleri (species) [taxon 33040], Human immunodeficiency virus 1 (no rank) [taxon 11676], Fusobacterium necrophorum (species) [taxon 859], Haemophilus influenzae (species) [taxon 727], Pseudomonas aeruginosa (species) [taxon 287], Staphylococcus aureus (species) [taxon 1280], Moraxella catarrhalis (species) [taxon 480], Peptostreptococcus (genus) [taxon 1257]

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13027759/full.md

---
Source: https://tomesphere.com/paper/PMC13027759